Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST palbociclib substudy for Rb-pathway altered advanced cancers
ACTRN12616000931471Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in cancer, sponsored by University of Sydney. Primary endpoint: Disease control. Started Nov 2016; status: completed.
02
Drugs
palbociclib
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12616000931471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000931471.